Active	Status	Sponsor type	Region	Phase	Filter
5 Active 0 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Hadaschik, Boris
NCT02106572 / 2013-003446-16: Therapeutic Instillation of Mistletoe	Recruiting	3	548	Europe, RoW	abnobaVISCUM 900, viscum album extract, mistletoe extract, abnobaVISCUM, Mitomycin C, MMC, Mitomycin	Abnoba Gmbh	Superficial Bladder Cancer	06/28	12/28
ARASAFE, NCT05676203: A Trial Comparing Docetaxel 75 mg/m2 (3w) Versus Docetaxel 50 mg/m2 (2w) in Combination With Darolutamide + ADT in mHSPC Patients	Recruiting	3	250	Europe	Standard ADT (androgen deprivation therapy), Standard Darolutamide, Docetaxel	Jena University Hospital, Bayer	Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)	07/25	01/27
PEACE6-Unfit, NCT04916613 / 2020-003663-26: ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)	Recruiting	3	300	Europe	Darolutamide 300 mg, Nubeqa®, Placebo, Androgen deprivation therapy, ADT	UNICANCER, Bayer	Prostate Cancer Metastatic	03/28	09/37
LPM-012, NCT04632251: Evaluation of the SENSEI® Laparoscopic Tethered Gamma Probe for 99mTc-nanocolloid Sentinel Lymph Node Biopsy in Prostate Cancer	Recruiting	N/A	56	Europe	SENSEI®	Lightpoint Medical Limited	Prostate Cancer	02/21	08/21